2-N-[2-[1-(difluoromethyl)pyrazol-3-yl]propan-2-yl]-6-(1-methylindazol-5-yl)-1,3,5-triazine-2,4-diamine
C18H19F2N9 — CID 171803216
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-N-[2-[1-(difluoromethyl)pyrazol-3-yl]propan-2-yl]-6-(1-methylindazol-5-yl)-1,3,5-triazine-2,4-diamine
2-N-[2-[1-(difluoromethyl)pyrazol-3-yl]propan-2-yl]-6-(1-methylindazol-5-yl)-1,3,5-triazine-2,4-diamine (PubChem CID 171803216) has the molecular formula C18H19F2N9 and a molecular weight of 399.41 g/mol. Its IUPAC name is 2-N-[2-[1-(difluoromethyl)pyrazol-3-yl]propan-2-yl]-6-(1-methylindazol-5-yl)-1,3,5-triazine-2,4-diamine.
Molecular Properties
| Compound Name | 2-N-[2-[1-(difluoromethyl)pyrazol-3-yl]propan-2-yl]-6-(1-methylindazol-5-yl)-1,3,5-triazine-2,4-diamine |
|---|---|
| PubChem CID | 171803216 |
| Molecular Formula | C18H19F2N9 |
| Molecular Weight | 399.41 g/mol |
| Exact Mass | 399.17 |
| IUPAC Name | 2-N-[2-[1-(difluoromethyl)pyrazol-3-yl]propan-2-yl]-6-(1-methylindazol-5-yl)-1,3,5-triazine-2,4-diamine |
| SMILES | Cn1ncc2cc(-c3nc(N)nc(NC(C)(C)c4ccn(C(F)F)n4)n3)ccc21 |
| InChI | InChI=1S/C18H19F2N9/c1-18(2,13-6-7-29(27-13)15(19)20)26-17-24-14(23-16(21)25-17)10-4-5-12-11(8-10)9-22-28(12)3/h4-9,15H,1-3H3,(H3,21,23,24,25,26) |
| InChIKey | WSAKLVZFQACMQC-UHFFFAOYSA-N |
| XLogP | 2.95 |
| TPSA | 112.36 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 399.41 |
| LogP ≤ 5 | 2.95 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 171803216 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.